Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK02 in Malignant Ascites from Advanced Solid Tumors
NCT07378436Phase 1Recruiting
- Sponsor
- Beijing Geek Gene Technology
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GK02 in malignant ascites, sponsored by Beijing Geek Gene Technology. Primary endpoints: Adverse Events at 12 months and Dose-Limiting Toxicities at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
GK02
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT07378436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07378436.